ANI PHARMACEUTICALS INC
ANI PHARMACEUTICALS INC (ANIP): 44 pipeline candidates · 5 upcoming catalysts · ~16 mo cash runway · 7 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
15.7 months
D/E 1.53
Lead: Approved
44 candidates
5 upcoming, next in ~72d
0 buys · 25 sells (180d)
A transparent, data-derived signal for ANI PHARMACEUTICALS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.8B
Cash
$311.2M
Quarterly Burn
$84.3M
Runway
15.7 mo
Revenue
$237.5M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (44 candidates)
| Drug | Phase |
|---|---|
| aspirin | Approved |
| baclofen | Approved |
| bexarotene | Approved |
| Botox® 100 Units | Phase 3 |
| carbamazepine | Approved |
| carboprost | Approved |
| ciprofloxacin | Approved |
| colestipol | Approved |
| Cortrophin Gel | Approved |
| dextroamp saccharate | Approved |
Showing 10 of 44 candidates. Sign up for full pipeline.
Upcoming Catalysts (5)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
277
Total value held
$1.83B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 2,747,492 | $211.3M |
| vanguard capital management llc | 1,646,128 | $126.6M |
| state street corp | 771,587 | $59.3M |
| tang capital management llc | 707,500 | $54.4M |
| goldentree asset management lp | 667,981 | $51.3M |
| deep track capital, lp | 600,000 | $46.1M |
| millennium management llc | 592,013 | $45.5M |
| arrowstreet capital, limited partnership | 564,360 | $43.4M |
| caption management, llc | 535,890 | $41.2M |
| dimensional fund advisors lp | 531,190 | $40.8M |
Showing top 10 of 277 institutional holders of ANI PHARMACEUTICALS INC. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in ANI PHARMACEUTICALS INC's pipeline?
ANI PHARMACEUTICALS INC (ANIP) has 44 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ANI PHARMACEUTICALS INC's lead drug candidate?
ANI PHARMACEUTICALS INC's most advanced tracked candidate is aspirin (Approved).
What is ANI PHARMACEUTICALS INC's next catalyst?
ANI PHARMACEUTICALS INC's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: BYVALSON" — expected August 29, 2026.
What is ANI PHARMACEUTICALS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ANI PHARMACEUTICALS INC has approximately 15.7 months of cash runway.
What is ANI PHARMACEUTICALS INC's market capitalization?
ANI PHARMACEUTICALS INC's market capitalization is approximately $1.8B.
Get the full picture on ANI PHARMACEUTICALS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.